• The Dominating and The Dominated

    Commentators have been going for months debating the merits of the New York/“hush money" prosecution of Donald Trump. Is it “serious"? Is it serious enough? How does it match up against the three

  • iPhone sales are plunging. Here’s why

    Apple’s smartphone sales tumbled 10% last quarter, according to market research firm IDC, as sales in China fell sharply. The company has lost momentum in China as nationalism, a rough economy and increased competition have hurt Apple over the past several months. “It’s a steep drop for Apple, but if you think of where we […]

  • 11 Hidden iPhone Features You Need to Check Out

    The iPhone, renowned for its intuitive design and plethora of features, continues to surprise users with functionalities lurking beneath its sleek interface. While many of us pride ourselves on our proficiency with this device, there’s always something new to learn. This guide dives into 11 lesser-known iPhone tricks that promise to refine your experience, streamline […]

  • iPhone SE 4: It reportedly borrows features from iPhone 13, iPhone XR

    Whether it's based on the iPhone 13, 14, or even XR, it seems like the new iPhone SE will be a big departure form the 2022 model.

    • CNBC

    Procter & Gamble raises earnings forecast but quarterly sales disappoint

    The Tide owner's quarterly volume was flat for the second consecutive

  • Tesla Plans To Lay Off 10% Of Workforce After Dismal Quarterly Sales

    After reporting dismal first-quarter sales, Tesla is planning to lay off about a tenth of its workforce as it tries to cut costs, multiple media outlets reported Monday. CEO Elon Musk detailed the plans in a memo sent to employees. The layoffs could affect about 14,000 of the 140,473 workers employed by the Austin, Texas, […]

  • Tesla plans to lay off 10% of workforce after dismal quarterly sales

    After reporting dismal first-quarter sales, Tesla is planning to lay off about a tenth of its workforce as it tries to cut costs, multiple media outlets reported Monday. CEO Elon Musk detailed the plans in a memo sent to employees. The layoffs could affect about 14,000 of the 140,473 workers

  • Tesla plans to lay off 10% of workforce after dismal quarterly sales

    DETROIT >> After reporting dismal first-quarter sales, Tesla is planning to lay off about a tenth of its workforce as it tries to cut costs, multiple media outlets reported today.

    • CNN

    Delta posts strong earnings in tough quarter for US airlines

    Delta Air Lines reported vastly improved earnings in the first quarter, and the company said results should remain strong the rest of the year. The Atlanta-based airline said its adjusted earnings came in at $380 million, or 45 cents a share, up from $217 million, up 75% from a year earlier. It easily topped Wall Street analysts’ consensus forecast of 36 cents a share. Revenue of $12.6 billion was up 6% and a record for the first three months of the year. It posted the increase despite the...

  • US Small-Business Optimism Falls to a More Than 11-Year Low

    US small-business optimism dropped to a more than 11-year low in March as

  • Abbott beats quarterly profit estimates on strong medical device sales

    Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday and raised the lower end of its annual forecast on robust sales of its medical devices, including glucose-monitoring products. Sales of Abbott's medical devices have been strengthened in recent quarters due to a resurgence in the demand for joint replacements as well as other surgeries delayed during the COVID-19 pandemic. Industry bellwether and rival Johnson & Johnson said on Tuesday it continues to expect...

  • J&J first-quarter revenue misses as Stelara sales disappoint

    Stelara sales were flat at $2.45 billion in the first quarter and came in below expectations of $2.6 billion, according to LSEG data. J&J has struck deals to delay U.S. launches of close-copy versions of Stelara until 2025, a key patent for which expired last year. Analysts have said the delayed competition will make the drug a larger contributor for J&J's 2024 and 2025 revenue than previously anticipated.